(Q36758847)

16 August 2017

1 reference

title

Bevacizumab for neovascular ocular diseases (English)

1 reference

16 August 2017

1 reference

Shalini S Lynch

1

1 reference

16 August 2017

Christine M Cheng

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

13 March 2007

1 reference

Annals of Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

41

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

614-625

1 reference

Causes and prevalence of visual impairment among adults in the United States

16 August 2017

cites work

1 reference

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration

21 January 2018

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

21 January 2018

1 reference

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 January 2018

1 reference

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments.

21 January 2018

1 reference

Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma

21 January 2018

1 reference

Case of anterior uveitis after intravitreal injection of bevacizumab

21 January 2018

1 reference

Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.

21 January 2018

1 reference

Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin)

21 January 2018

1 reference

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

Evolving guidelines for intravitreous injections

21 January 2018

1 reference

Evolving European guidance on the medical management of neovascular age related macular degeneration

21 January 2018

1 reference

Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing.

21 January 2018

1 reference

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study

21 January 2018

1 reference

Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H316

1 reference

16 August 2017

1 reference